Immune response to cyclin B1 in hepatocellular carcinoma

Giovanni Covini; Edward K.L. Chan; Mikio Nishioka; Syed Ahmed Morshed; Steven I. Reed; Eng M. Tan

doi:10.1002/hep.510250114

Immune response to cyclin B1 in hepatocellular carcinoma

Giovanni Covini, Edward K.L. Chan, Mikio Nishioka, Syed Ahmed Morshed, Steven I. Reed, Eng M. Tan

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Abstract

Proteins expressed by plasmids encoding human cyclins and cyclin- dependent kinase 2 (CDK2) were used as antigens in immunoblotting. Fifteen of 100 patients with hepatocellular carcinoma (HCC) were found to have autoantibodies reactive with cyclin B1 and with a 40-kd degradation product of cyclin B1-glutathione-S-transferase (GST) fusion protein. Only one serum was found to react with cyclin A and another single serum with CDK2 but no antibodies were detected to cyclin D1 and E. The basis for autoimmune responses to cyclin B1 in HCC are unknown at the present time but the possibilities might include aberrations in cyclin B1 regulation leading to altered product or its expression which resulted in stimulation of immune reactions.

Original language	English
Pages (from-to)	75-80
Number of pages	6
Journal	Hepatology
Volume	25
Issue number	1
DOIs	https://doi.org/10.1002/hep.510250114
State	Published - Jan 1997
Externally published	Yes

Access to Document

10.1002/hep.510250114

Cite this

@article{9e1144b666b0489ab624d73cad0b28e0,

title = "Immune response to cyclin B1 in hepatocellular carcinoma",

abstract = "Proteins expressed by plasmids encoding human cyclins and cyclin- dependent kinase 2 (CDK2) were used as antigens in immunoblotting. Fifteen of 100 patients with hepatocellular carcinoma (HCC) were found to have autoantibodies reactive with cyclin B1 and with a 40-kd degradation product of cyclin B1-glutathione-S-transferase (GST) fusion protein. Only one serum was found to react with cyclin A and another single serum with CDK2 but no antibodies were detected to cyclin D1 and E. The basis for autoimmune responses to cyclin B1 in HCC are unknown at the present time but the possibilities might include aberrations in cyclin B1 regulation leading to altered product or its expression which resulted in stimulation of immune reactions.",

author = "Giovanni Covini and Chan, {Edward K.L.} and Mikio Nishioka and Morshed, {Syed Ahmed} and Reed, {Steven I.} and Tan, {Eng M.}",

year = "1997",

month = jan,

doi = "10.1002/hep.510250114",

language = "English",

volume = "25",

pages = "75--80",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Immune response to cyclin B1 in hepatocellular carcinoma

AU - Covini, Giovanni

AU - Chan, Edward K.L.

AU - Nishioka, Mikio

AU - Morshed, Syed Ahmed

AU - Reed, Steven I.

AU - Tan, Eng M.

PY - 1997/1

Y1 - 1997/1

N2 - Proteins expressed by plasmids encoding human cyclins and cyclin- dependent kinase 2 (CDK2) were used as antigens in immunoblotting. Fifteen of 100 patients with hepatocellular carcinoma (HCC) were found to have autoantibodies reactive with cyclin B1 and with a 40-kd degradation product of cyclin B1-glutathione-S-transferase (GST) fusion protein. Only one serum was found to react with cyclin A and another single serum with CDK2 but no antibodies were detected to cyclin D1 and E. The basis for autoimmune responses to cyclin B1 in HCC are unknown at the present time but the possibilities might include aberrations in cyclin B1 regulation leading to altered product or its expression which resulted in stimulation of immune reactions.

AB - Proteins expressed by plasmids encoding human cyclins and cyclin- dependent kinase 2 (CDK2) were used as antigens in immunoblotting. Fifteen of 100 patients with hepatocellular carcinoma (HCC) were found to have autoantibodies reactive with cyclin B1 and with a 40-kd degradation product of cyclin B1-glutathione-S-transferase (GST) fusion protein. Only one serum was found to react with cyclin A and another single serum with CDK2 but no antibodies were detected to cyclin D1 and E. The basis for autoimmune responses to cyclin B1 in HCC are unknown at the present time but the possibilities might include aberrations in cyclin B1 regulation leading to altered product or its expression which resulted in stimulation of immune reactions.

UR - http://www.scopus.com/inward/record.url?scp=0031021286&partnerID=8YFLogxK

U2 - 10.1002/hep.510250114

DO - 10.1002/hep.510250114

M3 - Article

C2 - 8985268

AN - SCOPUS:0031021286

SN - 0270-9139

VL - 25

SP - 75

EP - 80

JO - Hepatology

JF - Hepatology

IS - 1

ER -

Immune response to cyclin B1 in hepatocellular carcinoma

Abstract

Access to Document

Fingerprint

Cite this